Tamiflu (Oseltamivir): Indications, Dosing, and Precautions
Oseltamivir is FDA-approved for treatment of influenza in patients ≥1 year old who have been symptomatic for no more than 2 days, and for prophylaxis in patients ≥1 year and older. 1
Treatment Indications
Who Must Receive Treatment
- All hospitalized children and adults with confirmed or suspected influenza should receive oseltamivir immediately, regardless of vaccination status or symptom duration 2
- Patients with severe, complicated, or progressive influenza requiring hospitalization 2
- High-risk patients should be treated irrespective of illness severity, including: 2
- Children <2 years old (increased hospitalization risk)
- Chronic pulmonary disease (including asthma)
- Cardiac disease, neurologic disorders, metabolic disorders
- Immunosuppression or immunocompromised state
- Chronic renal or hepatic disease
- Long-term aspirin therapy
Optional Treatment Scenarios
- Otherwise healthy patients with uncomplicated influenza when therapy can be started within 48 hours of symptom onset 2
- Healthy patients living with high-risk household contacts (e.g., infant <6 months or family member with high-risk conditions) 2
Treatment Dosing Regimens
Adults and Adolescents (≥13 years)
- 75 mg twice daily for 5 days 1
Pediatric Patients (≥1 year, weight-based)
- ≤15 kg: 30 mg twice daily 3, 2
- >15–23 kg: 45 mg twice daily 3, 2
- >23–40 kg: 60 mg twice daily 3, 2
- >40 kg: 75 mg twice daily 3, 2
- Duration: 5 days for all weight groups 1
Infants <1 Year (Not FDA-Approved)
- 3–11 months: 3 mg/kg twice daily for treatment 3
- <3 months: 3 mg/kg twice daily for treatment 3
- Neonates <14 days: WHO recommends 3 mg/kg once daily (lower doses should be considered) 3
- Premature infants: Not recommended due to immature renal function; if essential, consider 1 mg/kg twice daily with close monitoring 3
Renal Impairment (Adults)
- CrCl 10–30 mL/min: Reduce to 75 mg once daily for 5 days 1
- CrCl >30 mL/min: No dose adjustment needed 4
Prophylaxis Dosing Regimens
Adults and Adolescents (≥13 years)
- 75 mg once daily for at least 10 days after last known exposure 1
- Community outbreak: 75 mg once daily for up to 6 weeks 1
Pediatric Patients (≥1 year, weight-based)
- ≤15 kg: 30 mg once daily 4
- >15–23 kg: 45 mg once daily 4
- >23–40 kg: 60 mg once daily 4
- >40 kg: 75 mg once daily 4
- Duration: 10 days after exposure, may extend up to 6 weeks during community outbreak 4
Infants (Age-based)
- 9–11 months: 3.5 mg/kg once daily 4
- 3–8 months: 3 mg/kg once daily 4
- <3 months: Prophylaxis NOT recommended due to limited safety data 3, 4
Renal Impairment (Adults, Prophylaxis)
Timing of Initiation
Maximum benefit occurs when oseltamivir is started within 48 hours of symptom onset, reducing illness duration by approximately 17–30 hours and lowering otitis media risk by 34% 2. In adults, early treatment (within 24 hours) reduces symptom duration by 37–40% compared to placebo 5.
Treatment initiated after 48 hours may still provide benefit in moderate-to-severe or progressive disease, especially in high-risk or deteriorating patients 2. Recent observational data in hospitalized adults showed that oseltamivir started on the day of admission (regardless of symptom duration) reduced peak pulmonary disease severity, ICU admission, organ failure, and in-hospital death compared to late or no treatment 6.
Diagnostic Testing Considerations
- Do not delay antiviral therapy while awaiting test results when influenza is clinically suspected and treatment is indicated 2
- Rapid molecular assays (RNA detection, ≤20 min) have high sensitivity and specificity 2
- Rapid antigen tests have lower sensitivity (10–80%); a negative result should not exclude influenza in high-risk patients 2
Safety Profile and Adverse Effects
Treatment-Related Adverse Events
Adults:
- Nausea: 3.66% increased risk (NNTH = 28) 7
- Vomiting: 4.56% increased risk (NNTH = 22) 7
- Reduced diarrhea: 2.33% decreased risk (NNTB = 43) 7
- Reduced cardiac events: 0.68% decreased risk (NNTB = 148) 7
- Dose-response effect on psychiatric events observed at standard (150 mg/day) and high doses (300 mg/day) 7
Children:
- Vomiting: 5.34% increased risk (NNTH = 19), the only adverse event significantly more common than placebo 2, 7
- Overall tolerability is good in pediatric patients 2
Neuropsychiatric concerns reported from post-marketing surveillance have not been confirmed in controlled trials 2. However, patients with influenza (including those receiving oseltamivir), particularly pediatric patients, may be at increased risk of confusion or abnormal behavior early in their illness; monitor for signs of abnormal behavior 1.
Prophylaxis-Related Adverse Events
- Psychiatric events: 1.06% increased risk (NNTH = 94) during combined on- and off-treatment periods 7
- Headaches: 3.15% increased risk while on treatment (NNTH = 32) 7
- Renal events: 0.67% increased risk while on treatment (NNTH = 150) 7
- Nausea: 4.15% increased risk while on treatment (NNTH = 25) 7
Taking oseltamivir with food may improve gastrointestinal tolerability 4, 8.
Efficacy Data
Treatment Efficacy
Adults:
- Reduces time to first symptom alleviation by 16.8 hours (from 7 to 6.3 days) 7
- When started within 24 hours, reduces symptom duration by 43–47 hours (37–40% reduction) 5
- No significant effect on hospitalization in otherwise healthy adults 7
- Reduces self-reported, unverified pneumonia by 1.00% (NNTB = 100), but effect not significant in trials using detailed diagnostic criteria 7
Children:
- In otherwise healthy children, reduces symptom duration by 29 hours 7
- No effect in asthmatic children 7
- No significant effect on hospitalization or verified complications 7
Prophylaxis Efficacy
- Individual prophylaxis: Reduces symptomatic influenza by 3.05% (NNTB = 33) 7
- Household prophylaxis: Reduces symptomatic influenza by 13.6% (NNTB = 7) 7
- No significant effect on asymptomatic influenza 7
- Seasonal prophylaxis: >70% protective efficacy in unvaccinated adults; 92% efficacy when used adjunctively in vaccinated high-risk elderly patients 8
Important Precautions and Contraindications
Contraindications
- Known serious hypersensitivity to oseltamivir or any component of Tamiflu 1
Drug Interactions
- Live attenuated influenza vaccine (intranasal): Do not administer until 48 hours following cessation of oseltamivir; do not administer oseltamivir until 2 weeks following live vaccine unless medically indicated 1
Special Populations
- Pregnancy: No data in pregnant women; use only if clearly needed 1
- Nursing mothers: Caution should be exercised 1
- Pediatric use <1 year: Not FDA-approved; safety and efficacy not established 1
Common Pitfalls to Avoid
- Withholding treatment beyond 48 hours in high-risk or worsening patients may forfeit residual benefit; treatment can still be useful 2, 6
- Doubling the oseltamivir dose provides no additional clinical advantage over standard dosing 2
- Relying on a negative rapid antigen test to rule out influenza in high-risk patients can lead to missed treatment opportunities 2
- Delaying treatment while awaiting diagnostic confirmation in patients with clinical suspicion and treatment indications 2
- Using oseltamivir as a substitute for annual influenza vaccination; it is not a replacement for vaccination 1